Updated:
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. was established in 1994 by Pnina Fishman, a researcher who identified the therapeutic potential of A3 adenosine receptor...
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. was established in 1994 by Pnina Fishman, a researcher who identified the therapeutic potential of A3 adenosine receptor modulation. The company is headquartered in Petah Tikva, Israel, and trades publicly on the Tel Aviv Stock Exchange under ticker CFBI and on the US OTCQB under CANF. Its core technology platform centers on small-molecule agonists and antagonists targeting the A3 adenosine receptor, a G-protein-coupled receptor overexpressed in inflammatory and cancer cells. The firm's pipeline includes piclidenoson (CF101), in Phase 2/3 for psoriasis and Phase 2 for rheumatoid arthritis; namodenoson (CF102), in Phase 2 for liver cancer and non-alcoholic steatohepatitis (NASH); and CF602, a preclinical candidate for erectile dysfunction. Can-Fite has reported positive data from a Phase 2 liver cancer trial (per the American Society of Clinical Oncology, 2023). The company pursues a licensing-based revenue model, having out-licensed rights to piclidenoson for psoriasis in certain markets to partner companies such as Chong Kun Dang Pharmaceutical in South Korea (per the firm, 2021). Its geographic focus spans Israel, the United States, Europe, and Asia. As a publicly traded entity, Can-Fite does not report AUM or a professional headcount in a family-office context. The firm has funded its operations through public equity offerings, including a registered direct offering raising approximately $1.2 million in November 2024 (per SEC filing, November 2024). It maintains a single office in Petah Tikva and has not disclosed adjacent vehicles or philanthropic arms. Can-Fite differs from a typical biotechnology firm in its exclusive focus on the A3 adenosine receptor, a niche target pathway. This singular receptor approach creates both a clear mechanistic differentiator and a concentration risk. The company's public listing structure and reliance on equity financing shape its capital-allocation posture, with no direct-investment or family-office mandate reported.
General information
Firm type
other
Year founded
1994
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Petah Tikva
Corporate office
Petah Tikva, Israel
Principals
Pnina Fishman
Founder and Chief Scientific Officer
Motti Farbstein
Chief Executive Officer
Sector focus
Frequently asked questions
Who leads investment decisions at Can-Fite BioPharma?
Investment decisions are made by the CEO Motti Farbstein and the board of directors, which includes founder Pnina Fishman as Chief Scientific Officer. As a public company, strategic and financial decisions follow corporate governance procedures, with shareholder approval required for certain transactions (per the firm's proxy filings).
How does Can-Fite BioPharma fund its operations?
Can-Fite funds itself primarily through public equity offerings, including registered direct and at-the-market offerings. The firm raised approximately $1.2 million in a November 2024 direct offering (per SEC filing, November 2024). It has also generated licensing revenue through out-license agreements, such as the Chong Kun Dang Pharmaceutical partnership for piclidenoson in South Korea (per the firm, 2021).
What is Can-Fite's drug development strategy?
The firm exclusively develops small-molecule drugs targeting the A3 adenosine receptor, with a focus on repurposing candidates across multiple indications. Its lead compound, piclidenoson, is being studied initially for psoriasis and rheumatoid arthritis, while namodenoson targets liver cancer and NASH. The company pursues regulatory approvals in phases, with key clinical milestones reported at medical conferences.
What investment stages does Can-Fite target?
As a clinical-stage biotechnology company, Can-Fite does not target investment stages typical of asset managers. Its capital allocation is directed at late-clinical and early-commercialization drug candidates, with a shift toward revenue generation through licensing and partnerships rather than direct venture or private equity investments.
How is Can-Fite structured relative to a family office?
Can-Fite is a publicly traded biotechnology company, not a family office or asset manager. No family-office wealth or wealth-origin relationship has been publicly disclosed. The firm's structure is corporate, with operations managed by an executive team under a board of directors and overseen by public company regulations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: